Education
About Us
Working with TipRanks
Follow Us
ESSA Pharma Inc (EPIX)
NASDAQ:EPIX
EPIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.40 - $9.60
Previous CloseN/A
Volume26.72K
Average Volume (3M)210.56K
Market Cap
$73.68M
Enterprise Value$142.43M
Total Cash (Recent Filing)$93.31M
Total Debt (Recent Filing)$305.04K
Price to Earnings (P/E)―
Beta2.15
Next Earnings
May 13, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding44,388,550
10 Day Avg. Volume83,349
30 Day Avg. Volume210,564
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.39
Forecast
1Y Price Target
$2.25Price Target Upside35.54% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
ESSA Pharma News
PremiumCompany Announcements
ESSA Pharma Inc. Explores Strategic Options Amid Losses
PremiumCompany Announcements
ESSA Pharma Reports Q1 Loss, Explores Strategic Options
PremiumCompany Announcements
ESSA Pharma Inc. Reports Strategic Shift Amid Losses---
Bulls Say, Bears Say
Bulls Say
Financial PositionEPIX's last reported cash balance of $126.8M offers flexibility to evaluate opportunities.
Bears Say
Clinical Trial ResultsThe futility analysis revealed that the enzalutamide monotherapy control arm was performing better than historical controls and similar to the masofaniten + enzalutamide combo.
Product DevelopmentMasofanetin failed to fulfill its promise of overcoming prostate cancer resistance through N-terminal domain inhibition.
---
Ownership Overview
2.17% Insiders
0.06% Mutual Funds
59.87% Other Institutional Investors
37.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
EPIX FAQ
What was ESSA Pharma Inc’s price range in the past 12 months?
ESSA Pharma Inc lowest stock price was $1.40 and its highest was $9.60 in the past 12 months.
What is ESSA Pharma Inc’s market cap?
ESSA Pharma Inc’s market cap is $73.68M.
When is ESSA Pharma Inc’s upcoming earnings report date?
ESSA Pharma Inc’s upcoming earnings report date is May 13, 2025 which is in 68 days.
How were ESSA Pharma Inc’s earnings last quarter?
ESSA Pharma Inc released its earnings results on Feb 11, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.18 by -$0.01.
Is ESSA Pharma Inc overvalued?
According to Wall Street analysts ESSA Pharma Inc’s price is currently Undervalued.
Does ESSA Pharma Inc pay dividends?
ESSA Pharma Inc does not currently pay dividends.
What is ESSA Pharma Inc’s EPS estimate?
ESSA Pharma Inc’s EPS estimate is -0.12.
How many shares outstanding does ESSA Pharma Inc have?
ESSA Pharma Inc has 44,388,550 shares outstanding.
What happened to ESSA Pharma Inc’s price movement after its last earnings report?
ESSA Pharma Inc reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.18. Following the earnings report the stock price went down -3.012%.
Which hedge fund is a major shareholder of ESSA Pharma Inc?
Currently, no hedge funds are holding shares in EPIX
---
ESSA Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.25 (35.54% Upside)
$2.25 (35.54% Upside)
Blogger Sentiment
Bullish
EPIX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 4.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.85%
12-Months-Change
Fundamentals
Return on Equity
-25.37%
Trailing 12-Months
Asset Growth
-15.13%
Trailing 12-Months
Company Description
ESSA Pharma Inc
ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
---
EPIX Stock 12 Month Forecast
Average Price Target
$2.25
▲(35.54% Upside)
Technical Analysis
Exelixis
―
Madrigal Pharmaceuticals
―
Karyopharm Therapeutics
―
Arvinas Holding Company
―
Biohaven Ltd.
―
---